How much weight comes back after stopping?
For most people, about two-thirds within a year. The STEP 1 trial extension followed 327 people after both semaglutide and the trial’s lifestyle program ended at week 68.
| Point in time | Semaglutide group | Placebo group |
|---|---|---|
| Weight change, week 0 to 68 (on treatment) | -17.3% | -2.0% |
| Regained, week 68 to 120 (off treatment) | +11.6 points | +1.9 points |
| Net change, week 0 to 120 | -5.6% | -0.1% |
Averages hide individual differences, so your own course may be better or worse. Still, the authors concluded that ongoing treatment appears to be needed to keep the improvements, and that the pattern reflects obesity as a chronic condition.
Why does appetite rebound?
Because the medicine was doing much of the appetite control. MedlinePlus explains that semaglutide slows stomach emptying and may decrease appetite. When it wears off, meals stop feeling as filling and hunger signals return to their old strength, while your body is now smaller and burns fewer calories than before.
That combination, more hunger and a lower energy need, is why weight drifts back even when you feel you are eating “normally.” The Wegovy label puts semaglutide’s half-life at about a week, with the drug present for five to seven weeks after the final injection, so the rebound builds over weeks.
What happens to blood pressure, blood sugar and cholesterol?
Most of the gains fade along with the weight. In the STEP 1 extension, improvements in blood pressure, A1C, lipids and C-reactive protein seen at week 68 moved back toward baseline by week 120 for most measures. Among people who started with prediabetes, the share with normal blood sugar fell from 93.6% on treatment to 43.3% a year after stopping. Our page on semaglutide and prediabetes covers that in detail.
If you take medicines for blood pressure or diabetes that were lowered while you were on semaglutide, stopping matters for them too. Those doses may need to go back up as weight returns, so the clinician who manages them should know your plan.
Stopping early: what the STEP 4 trial showed
Stopping after only a few months produced the same rebound pattern. In the STEP 4 trial, everyone took semaglutide for 20 weeks and lost an average of 10.6%. Those then switched to placebo gained 6.9% over the next 48 weeks, while those who continued lost another 7.9%. Tirzepatide shows the same pattern: in SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% over a year.
How can you plan for stopping?
Treat it as a project with a start date, not an event. The pieces that matter most:
- Decide the goal. Stop completely, or find the lowest dose that holds your weight.
- Step down rather than stop cold, if your provider agrees; see how to taper off semaglutide.
- Lift and eat protein before the appetite brake comes off, so muscle carries you through.
- Set a weight range that triggers a check-in, so a five-pound drift gets attention before it becomes twenty.
- Recheck labs a few months after stopping to see where blood sugar and lipids land.
Pausing for surgery is a separate question; see stopping semaglutide before surgery.
Related question: is staying on it long term an option?
For some people, yes. Semaglutide for weight is approved for long-term use alongside diet and activity, and a lower maintenance dose can be part of that discussion. The pros and cons are covered in our semaglutide medication guide and the coming off a GLP-1 maintenance plan guide.
How Ultimate Male helps you stop well
At Ultimate Male, the exit is planned before the last dose. Your PA-C or MD looks at your body composition, labs, how long your weight has been stable and how you eat and train, then agrees on whether to taper, how to monitor, and what would prompt a change of course.
Check-ins continue after the medicine stops, because the months after stopping are when early regain is easiest to catch. If you are on semaglutide now and thinking about stopping, talk to the medical weight loss team first. A free 10-minute call at 626-319-5261 is enough to get started.
